CHRONIC IMMUNOLOGICAL DISEASES AND TREATMENT FAILURE

Chronic immunological diseases require treatment over an extended period of time. After a while, the brand name biologic or biosimilar treatment might stop working for a particular patient – this is called a treatment failure.1

Clinical trials have shown that a substantial proportion of patients
experience treatment failure
. This can result from patients:2

  • img16

    Failing to respond to treatment or having an inadequate response (called “primary failure”)

  • img17

    Losing response to treatment over time (called “secondary failure”)

  • img18

    Developing an adverse event

Treatment failure often results in patients switching to a different biologic therapy.3

For example, in rheumatoid arthritis, international treatment guidelines recommend that a new biologic therapy be considered after treatment failure, either from the same biologic class (i.e. the same target) or a different class (i.e. a new target) altogether.3

img19

After treatment failure, patients may be
SWITCHED TO A BIOLOGIC TREATMENT
OPTION
that has a DIFFERENT TARGET3

img20

Patients may require MULTIPLE BRAND NAME BIOLOGICS AND BIOSIMILARS over the course of their disease